Aerie Pharmaceuticals is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Co.'s commercial products include Rhopressa®, which is a once-daily eye drop to lower elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension; and Rocklatan®, which is a once-daily fixed-dose combination of Rhopressa® and latanoprost, the prescribed drug for the treatment of patients with open-angle glaucoma. Co. is developing three sustained-release implants focused on retinal diseases, AR-1105, AR-13503 SR and AR-14034 SR. We show 35 historical shares outstanding datapoints in our coverage of AERI's shares outstanding history.
Understanding the changing numbers of AERI shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AERI versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AERI by allowing them to research AERI shares outstanding history
as well as any other stock in our coverage universe. |
Free AERI Email Alerts:
Video: Shares Outstanding Importance
